2024年2月14日 · Beactica Therapeutics is a precision oncology company developing novel, life-saving small molecule therapeutics to treat genetically defined cancers with significant unmet clinical need. Explore more

2024年2月14日 · Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research’s Annual Meeting 2024. The conference will take place on April 5–10, 2024 in San Diego, California.

2023年9月26日 · Beactica Therapeutics AB, the Swedish precision oncology company, today announced that it has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS), one of 27 institutes and centers at the U.S. National Institutes of Health (NIH).

TEAD 抑制剂 (Beactica): 一种TEAD 抑制剂药物，由Beactica Therapeutics AB (Beactica Therapeutics AB)公司最早进行研发，目前全球最高研发状态为临床前，作用机制: TEAD 抑制剂(TEA domain transcription factors inhibitors)，治疗领域: 肿瘤，在研适应症: 肿瘤，在研机构: Beactica Therapeutics AB。

根据协议，NCATS将使用Beactica专有的TEAD靶向降解剂，在疾病相关临床前模型中评价其功效。NCATS还将使用约3000种针对肿瘤的机械注释药物进行高通量药物组合筛选，系统地展现特定临床前候选药物组合的情况。12.

2024年2月14日 · Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for...

2024年2月14日 · The presentation will include new positive results from studies with novel proteolysis-targeting degraders of TEAD based on interface 3-binding ligands under development by Beactica.

2023年9月26日 · Under the agreement, NCATS will gain access to proprietary targeted degraders of TEAD from Beactica to evaluate their efficacy in disease-relevant preclinical models.

2024年2月14日 · The presentation will include new positive results from studies with novel proteolysis-targeting degraders of TEAD based on interface 3-binding ligands under development by Beactica. This will include head-to-head in vitro comparisons with other classes of TEAD modulators in clinical development such as palmitoylation inhibitors and direct YAP ...

TEAD modulators/degraders were evaluated against TEAD-dependent mesothelioma cell lines and TEAD-independent uveal melanoma cell lines in a CellTiter-Glo assay after 48 h incubation.